134 Financial Statements 2 Operating profit Operating profit includes the following items: Selling, general and administrative costs AstraZeneca is defending its interests in various federal and state investigations and civil litigation matters relating to drug marketing and pricing practices and in respect of which the Company has made provisions in aggregate of $636m during 2009.
$524m of this has been made in respect of the US Attorneys Office investigation into sales and marketing practices involving Seroquel and $112m relates to average wholesale price litigation.
The current status of these matters is described in Note 25.
These provisions constitute our best estimate at the time of losses expected for these matters.
Other operating income and expense 2009 2008 2007 $m $m $m Royalties Income 255 288 236 Amortisation 79 84 Impairment 150 91 Net gain on disposal of property, plant and equipment 8 6 9 Gains on disposal of product rights 170 Net gain loss on disposal of other intangible assets 1 17 1 Gains on divestments of non-core products 216 118 192 Impairment of intangible assets relating to future licensing and contractual income 115 Other income 265 304 310 Other expense 18 18 Other operating income and expense 553 524 728 Royalty amortisation relates to income streams acquired with MedImmune.
The amortisation in 2007 $53m was posted to SG&A and not adjusted.
Restructuring and synergy costs During 2009 the Group continued the restructuring and synergy programmes approved by the SET and announced in 2007 and 2008.
In addition, the Group announced further programmes during the year.
The tables below show the costs that have been charged in respect of these programmes by cost category and type.
Severance provisions are detailed in Note 18.
2009 2008 2007 $m $m $m Cost of sales 188 405 415 Research and development 68 166 73 Selling, general and administrative costs 403 310 478 Total charge 659 881 966 2009 2008 2007 $m $m $m Severance costs 262 499 678 Accelerated depreciation and impairment 148 219 203 Other 249 163 85 Total charge 659 881 966 3 Finance income and expense 2009 2008 2007 $m $m $m Finance income Returns on fixed deposits and equity securities 20 15 52 Returns on short-term deposits 22 127 298 Expected return on post-employment defined benefit plan assets 388 584 573 Fair value gains on debt, interest rate swaps and investments 1 128 36 Net exchange gains 31 Total 462 854 959 AstraZeneca Annual Report and Form 20-F Information 2009
